# Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers

> **NCT01340898** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 753 (actual)

## Conditions studied

- Meningococcal Infection

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK 134612
- **BIOLOGICAL:** SynflorixTM
- **BIOLOGICAL:** Infanrix-IPV/HiberixTM

## Key facts

- **NCT ID:** NCT01340898
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-27
- **Primary completion:** 2014-08-04
- **Final completion:** 2015-10-19
- **Target enrollment:** 753 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340898, "Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01340898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*